• Reported GAAP EPS of $0.18 down -5.26% YoY • Reported revenue of $89.09M up 33.31% YoY • Harrow Health Inc expects full-year 2026 revenue guidance of $350M to $365M and full-year 2026 Adjusted EBITDA guidance of $80M to $100M.
Bullish
Harrow Health Inc achieved strong Q4 and full-year revenue growth, generated significant operating cash flow, and saw key products gaining traction. The company also plans strategic expansion and future product launches.
Bearish
Harrow Health Inc experienced a decrease in stockholders' equity and increased debt, alongside rising R&D and other expenses. Management also noted a need for improved clarity in financial guidance.